Literature DB >> 33672425

Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach.

Simona De Summa1, Antonio Palazzo2, Mariapia Caputo1, Rosa Maria Iacobazzi3, Brunella Pilato1, Letizia Porcelli3, Stefania Tommasi1, Angelo Virgilio Paradiso4, Amalia Azzariti3.   

Abstract

Prostate cancer is one of the most common malignancies in men. It is characterized by a high molecular genomic heterogeneity and, thus, molecular subtypes, that, to date, have not been used in clinical practice. In the present paper, we aimed to better stratify prostate cancer patients through the selection of robust long non-coding RNAs. To fulfill the purpose of the study, a bioinformatic approach focused on feature selection applied to a TCGA dataset was used. In such a way, LINC00668 and long non-coding(lnc)-SAYSD1-1, able to discriminate ERG/not-ERG subtypes, were demonstrated to be positive prognostic biomarkers in ERG-positive patients. Furthermore, we performed a comparison between mutated prostate cancer, identified as "classified", and a group of patients with no peculiar genomic alteration, named "not-classified". Moreover, LINC00920 lncRNA overexpression has been linked to a better outcome of the hormone regimen. Through the feature selection approach, it was found that the overexpression of lnc-ZMAT3-3 is related to low-grade patients, and three lncRNAs: lnc-SNX10-87, lnc-AP1S2-2, and ADPGK-AS1 showed, through a co-expression analysis, significant correlation values with potentially druggable pathways. In conclusion, the data mining of publicly available data and robust bioinformatic analyses are able to explore the unknown biology of malignancies.

Entities:  

Keywords:  feature selection; lncRNA; prostate cancer

Mesh:

Substances:

Year:  2021        PMID: 33672425      PMCID: PMC7926489          DOI: 10.3390/ijms22042227

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  71 in total

Review 1.  Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.

Authors:  Dharam Kaushik; Vishal Vashistha; Sudhir Isharwal; Soud A Sediqe; Ming-Fong Lin
Journal:  Ther Adv Urol       Date:  2015-12

2.  European cancer mortality predictions for the year 2020 with a focus on prostate cancer.

Authors:  G Carioli; P Bertuccio; P Boffetta; F Levi; C La Vecchia; E Negri; M Malvezzi
Journal:  Ann Oncol       Date:  2020-04-19       Impact factor: 32.976

3.  Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Philippe Beuzeboc
Journal:  Eur Urol       Date:  2011-03-01       Impact factor: 20.096

4.  TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

Authors:  Alexandra M Blee; Yundong He; Yinhui Yang; Zhenqing Ye; Yuqian Yan; Yunqian Pan; Tao Ma; Joseph Dugdale; Emily Kuehn; Manish Kohli; Rafael Jimenez; Yu Chen; Wanhai Xu; Liguo Wang; Haojie Huang
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

5.  Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor βcx in human prostate carcinoma.

Authors:  S Nagasaki; Y Nakamura; T Maekawa; J Akahira; Y Miki; T Suzuki; S Ishidoya; Y Arai; H Sasano
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

6.  Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer.

Authors:  Constantinos Constantinides; Andreas C Lazaris; Konstantinos N Haritopoulos; Dimitrios Pantazopoulos; Michalis Chrisofos; Aris Giannopoulos
Journal:  World J Urol       Date:  2003-07-05       Impact factor: 4.226

7.  A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.

Authors:  N M Hahn; R T Zon; M Yu; F O Ademuyiwa; T Jones; W Dugan; C Whalen; R Shanmugam; T Skaar; C J Sweeney
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

8.  Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

Authors:  Kalipso Halkidou; Luke Gaughan; Susan Cook; Hing Y Leung; David E Neal; Craig N Robson
Journal:  Prostate       Date:  2004-05-01       Impact factor: 4.104

9.  Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression.

Authors:  Yu Wang; Russell J Ledet; Keren Imberg-Kazdan; Susan K Logan; Michael J Garabedian
Journal:  Oncotarget       Date:  2016-08-02

10.  LNCipedia 5: towards a reference set of human long non-coding RNAs.

Authors:  Pieter-Jan Volders; Jasper Anckaert; Kenneth Verheggen; Justine Nuytens; Lennart Martens; Pieter Mestdagh; Jo Vandesompele
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  1 in total

1.  Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.

Authors:  Hongpan Zhang; Meihan Liu; Zhihao Yang; Guobo Du; Bin Yu; Yan Gui; Lu Cao; Xianfu Li; Bangxian Tan
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.